JP2019089849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019089849A5 JP2019089849A5 JP2019043998A JP2019043998A JP2019089849A5 JP 2019089849 A5 JP2019089849 A5 JP 2019089849A5 JP 2019043998 A JP2019043998 A JP 2019043998A JP 2019043998 A JP2019043998 A JP 2019043998A JP 2019089849 A5 JP2019089849 A5 JP 2019089849A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- treating
- compound
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161551772P | 2011-10-26 | 2011-10-26 | |
| US61/551,772 | 2011-10-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016150311A Division JP6496689B2 (ja) | 2011-10-26 | 2016-07-29 | ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019089849A JP2019089849A (ja) | 2019-06-13 |
| JP2019089849A5 true JP2019089849A5 (https=) | 2019-11-14 |
| JP6804580B2 JP6804580B2 (ja) | 2020-12-23 |
Family
ID=47116500
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538876A Active JP5982001B2 (ja) | 2011-10-26 | 2012-10-23 | ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体 |
| JP2016150311A Active JP6496689B2 (ja) | 2011-10-26 | 2016-07-29 | ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体 |
| JP2019043998A Active JP6804580B2 (ja) | 2011-10-26 | 2019-03-11 | ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538876A Active JP5982001B2 (ja) | 2011-10-26 | 2012-10-23 | ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体 |
| JP2016150311A Active JP6496689B2 (ja) | 2011-10-26 | 2016-07-29 | ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体 |
Country Status (32)
| Country | Link |
|---|---|
| US (9) | US8658803B2 (https=) |
| EP (2) | EP3078656B1 (https=) |
| JP (3) | JP5982001B2 (https=) |
| KR (1) | KR102051687B1 (https=) |
| CN (2) | CN104114164B (https=) |
| AR (2) | AR088535A1 (https=) |
| AU (3) | AU2012329098B2 (https=) |
| BR (2) | BR122019025505B1 (https=) |
| CA (1) | CA2853648C (https=) |
| CL (1) | CL2014001080A1 (https=) |
| CO (1) | CO6960509A2 (https=) |
| CY (1) | CY1121604T1 (https=) |
| DK (1) | DK2770989T3 (https=) |
| ES (2) | ES2708997T3 (https=) |
| HR (1) | HRP20181934T1 (https=) |
| HU (1) | HUE040145T2 (https=) |
| IL (3) | IL232204B (https=) |
| IN (1) | IN2014DN03424A (https=) |
| LT (1) | LT2770989T (https=) |
| MX (2) | MX376348B (https=) |
| MY (1) | MY172013A (https=) |
| PH (2) | PH12014500928B1 (https=) |
| PL (1) | PL2770989T3 (https=) |
| PT (1) | PT2770989T (https=) |
| RS (1) | RS58111B1 (https=) |
| RU (2) | RU2744577C2 (https=) |
| SG (2) | SG11201401818RA (https=) |
| SI (1) | SI2770989T1 (https=) |
| TW (1) | TWI631099B (https=) |
| UA (1) | UA115043C2 (https=) |
| WO (1) | WO2013062947A1 (https=) |
| ZA (1) | ZA201403222B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| AU2012329098B2 (en) * | 2011-10-26 | 2017-08-03 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| KR102223384B1 (ko) * | 2013-03-06 | 2021-03-05 | 알러간, 인코포레이티드 | 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도 |
| AU2014225992B2 (en) * | 2013-03-06 | 2018-03-22 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| RU2696581C2 (ru) * | 2013-07-16 | 2019-08-05 | Аллерган, Инк. | Производные n-мочевинозамещенных аминокислот как модуляторы формил-пептидного рецептора |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| TWI537251B (zh) | 2013-10-09 | 2016-06-11 | 長庚大學 | Ｆｐｒ１拮抗劑的衍生物及其用途 |
| RU2703725C1 (ru) * | 2013-11-21 | 2019-10-22 | Аллерган, Инк. | Производные фенилкарбамата в качестве модуляторов формилпептидного рецептора |
| NZ720508A (en) | 2013-11-28 | 2019-03-29 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| WO2015179707A1 (en) * | 2014-05-21 | 2015-11-26 | Allergan, Inc. | Imidazole derivatives as formyl peptide receptor modulators |
| WO2016189876A1 (en) | 2015-05-27 | 2016-12-01 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| JP6746614B2 (ja) | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| TW201718473A (zh) * | 2015-08-05 | 2017-06-01 | 歐樂根公司 | 作為甲醯肽受體１（ｆｐｒ１）選擇性促效劑之苯基脲類似物 |
| CN109715602A (zh) | 2016-03-28 | 2019-05-03 | 阿勒根公司 | 苯基脲衍生物作为n-甲酰肽受体调节剂 |
| EP3442950A1 (en) | 2016-04-12 | 2019-02-20 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
| RU2768587C2 (ru) * | 2016-10-06 | 2022-03-24 | Дайити Санкио Компани, Лимитед | Производное мочевины |
| JP2020015664A (ja) * | 2016-11-21 | 2020-01-30 | 宇部興産株式会社 | 含窒素多環式ヘテロ環誘導体 |
| US10608869B2 (en) * | 2017-03-20 | 2020-03-31 | Nicira, Inc. | Handling control-plane connectivity loss in virtualized computing environments |
| KR102803660B1 (ko) | 2018-03-05 | 2025-05-02 | 브리스톨-마이어스 스큅 컴퍼니 | 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제 |
| EP4234014A1 (en) * | 2022-02-28 | 2023-08-30 | Insusense ApS | Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases |
| WO2025144935A1 (en) * | 2023-12-26 | 2025-07-03 | Development Center For Biotechnology | Heterocycle compounds as formyl peptide receptor modulators |
| WO2025233915A1 (en) | 2024-05-10 | 2025-11-13 | Allgenesis Biotherapeutics Inc. | Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2533210A1 (fr) * | 1982-09-17 | 1984-03-23 | Lyon I Universite Claude | Edulcorants de synthese |
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| US5284828A (en) | 1990-05-14 | 1994-02-08 | Fujisawa Pharmaceutical Co. Ltd. | Peptide compound and its preparation |
| JP3387948B2 (ja) | 1992-12-04 | 2003-03-17 | 富山化学工業株式会社 | 新規なフェニルアラニン誘導体またはその塩 |
| AU667995B2 (en) * | 1993-02-15 | 1996-04-18 | Bayer Aktiengesellschaft | New pseudopeptides having an antiviral action |
| NZ275691A (en) * | 1993-11-05 | 1998-03-25 | Warner Lambert Co | Di and tripeptides and compositions thereof which inhibit farnesyl transferase |
| JPH11171896A (ja) * | 1995-09-19 | 1999-06-29 | Kirin Brewery Co Ltd | 新規ペプチド化合物およびその医薬組成物 |
| US6423689B1 (en) * | 1997-12-22 | 2002-07-23 | Warner-Lambert Company | Peptidyl calcium channel blockers |
| US6548637B1 (en) * | 1998-06-18 | 2003-04-15 | Sepracor, Inc. | Ligands for opioid receptors |
| US6243689B1 (en) | 1998-12-29 | 2001-06-05 | Robert G. Norton | System and method for authorizing electronic funds transfer at a point of sale |
| WO2001014328A2 (en) | 1999-08-20 | 2001-03-01 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
| EP1162194A1 (en) | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| DE10063008A1 (de) | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| WO2002068586A2 (en) * | 2001-01-19 | 2002-09-06 | The Scripps Research Institute | Hiv/fiv protease inhibitors |
| DK1453852T3 (da) * | 2001-12-12 | 2007-05-21 | Wilex Ag | Selektive arylguanidinpeptider som urokinaseinhibitorer |
| MXPA05002493A (es) | 2002-09-05 | 2005-05-27 | Neurosearch As | Derivados de diarilurea y su uso como bloqueadores del canal del cloro. |
| US7645903B2 (en) * | 2002-10-31 | 2010-01-12 | Ge Healthcare Bio-Sciences Ab | Use of urea variants as affinity ligands |
| US7943137B2 (en) | 2002-11-07 | 2011-05-17 | Takeda Pharmaceutical Company Limited | FPRL1 ligands and use thereof |
| KR100527361B1 (ko) * | 2003-04-01 | 2005-11-09 | 주식회사 프로메디텍 | 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물 |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| CN1894580A (zh) * | 2003-11-07 | 2007-01-10 | 阿卡蒂亚药品公司 | 脂氧素受体fprl1作为一种用于鉴定能有效治疗疼痛和炎症化合物的工具 |
| AU2004290368A1 (en) * | 2003-11-07 | 2005-05-26 | Acadia Pharmaceuticals Inc. | Use of the lipoxin receptor, FPRL1, as a tool for identifying compounds effective in the treatment of pain and inflammation |
| JP4769082B2 (ja) | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | ウレア誘導体、その製造法及び用途 |
| GB0417802D0 (en) | 2004-08-10 | 2004-09-15 | Novartis Ag | Organic compounds |
| CN101048384A (zh) | 2004-10-28 | 2007-10-03 | 默克公司 | 促代谢型谷氨酸盐受体的嘧啶和喹啉增效剂 |
| WO2006063113A2 (en) | 2004-12-07 | 2006-06-15 | Portola Pharmaceuticals, Inc. | Ureas as factor xa inhibitors |
| WO2006065755A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| EP2064234B1 (en) | 2006-09-18 | 2011-11-02 | Compugen Ltd. | Bioactive peptides and method of using same |
| AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| KR20090121832A (ko) | 2008-05-23 | 2009-11-26 | 인제대학교 산학협력단 | 2-(2-히드록시벤조일)히드라진카르복시아미드 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를유효 성분으로 함유하는 선택적 면역 억제용 약학적 조성물 |
| US20100035932A1 (en) | 2008-08-07 | 2010-02-11 | Schepetkin Igor A | Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof |
| CA2747995A1 (en) * | 2008-12-23 | 2010-07-01 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| CA2803920A1 (en) | 2010-06-24 | 2011-12-29 | Richard Beard | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| CA2819457A1 (en) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| EP2673263A1 (en) | 2011-02-11 | 2013-12-18 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators |
| US8653299B2 (en) | 2011-03-17 | 2014-02-18 | Allergan, Inc. | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US20120329873A1 (en) | 2011-06-17 | 2012-12-27 | Li yong-xin | D-serine for the treatment of visual system disorders |
| GB2494851A (en) * | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| EP2731931A1 (en) | 2011-07-11 | 2014-05-21 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| AU2012329098B2 (en) | 2011-10-26 | 2017-08-03 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8492556B2 (en) | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8541577B2 (en) | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| EP2814815A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators |
| ES2711363T3 (es) | 2012-04-16 | 2019-05-03 | Allergan Inc | Derivados de (2-ureidoacetamido)alquilo como moduladores del receptor 2 de péptidos formilados |
| AU2014225992B2 (en) | 2013-03-06 | 2018-03-22 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| KR102223384B1 (ko) | 2013-03-06 | 2021-03-05 | 알러간, 인코포레이티드 | 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도 |
| RU2696581C2 (ru) | 2013-07-16 | 2019-08-05 | Аллерган, Инк. | Производные n-мочевинозамещенных аминокислот как модуляторы формил-пептидного рецептора |
| WO2015042071A1 (en) | 2013-09-19 | 2015-03-26 | Allergan, Inc. | Diphenyl urea derivatives as formyl peptide receptor modulators |
| JP6172288B2 (ja) | 2013-10-24 | 2017-08-02 | トヨタ自動車株式会社 | ナトリウム電池用正極活物質及びナトリウム電池 |
| RU2703725C1 (ru) | 2013-11-21 | 2019-10-22 | Аллерган, Инк. | Производные фенилкарбамата в качестве модуляторов формилпептидного рецептора |
| WO2015179707A1 (en) | 2014-05-21 | 2015-11-26 | Allergan, Inc. | Imidazole derivatives as formyl peptide receptor modulators |
-
2012
- 2012-10-23 AU AU2012329098A patent/AU2012329098B2/en active Active
- 2012-10-23 JP JP2014538876A patent/JP5982001B2/ja active Active
- 2012-10-23 PH PH1/2014/500928A patent/PH12014500928B1/en unknown
- 2012-10-23 CN CN201280058845.5A patent/CN104114164B/zh active Active
- 2012-10-23 US US13/658,523 patent/US8658803B2/en active Active
- 2012-10-23 WO PCT/US2012/061448 patent/WO2013062947A1/en not_active Ceased
- 2012-10-23 ES ES12781009T patent/ES2708997T3/es active Active
- 2012-10-23 PH PH1/2019/500171A patent/PH12019500171B1/en unknown
- 2012-10-23 DK DK12781009.1T patent/DK2770989T3/en active
- 2012-10-23 SG SG11201401818RA patent/SG11201401818RA/en unknown
- 2012-10-23 MX MX2018008879A patent/MX376348B/es unknown
- 2012-10-23 UA UAA201405510A patent/UA115043C2/uk unknown
- 2012-10-23 PL PL12781009T patent/PL2770989T3/pl unknown
- 2012-10-23 RU RU2017129434A patent/RU2744577C2/ru active
- 2012-10-23 KR KR1020147014057A patent/KR102051687B1/ko active Active
- 2012-10-23 HR HRP20181934TT patent/HRP20181934T1/hr unknown
- 2012-10-23 RU RU2014120013A patent/RU2629205C2/ru active
- 2012-10-23 IN IN3424DEN2014 patent/IN2014DN03424A/en unknown
- 2012-10-23 ES ES16168916T patent/ES2820714T3/es active Active
- 2012-10-23 EP EP16168916.1A patent/EP3078656B1/en active Active
- 2012-10-23 MY MYPI2014001210A patent/MY172013A/en unknown
- 2012-10-23 BR BR122019025505-9A patent/BR122019025505B1/pt not_active IP Right Cessation
- 2012-10-23 CA CA2853648A patent/CA2853648C/en active Active
- 2012-10-23 RS RS20181396A patent/RS58111B1/sr unknown
- 2012-10-23 BR BR112014010042-0A patent/BR112014010042B1/pt active IP Right Grant
- 2012-10-23 EP EP12781009.1A patent/EP2770989B1/en active Active
- 2012-10-23 MX MX2014005047A patent/MX357737B/es active IP Right Grant
- 2012-10-23 CN CN201610971347.XA patent/CN106518742B/zh active Active
- 2012-10-23 LT LTEP12781009.1T patent/LT2770989T/lt unknown
- 2012-10-23 SG SG10201903266YA patent/SG10201903266YA/en unknown
- 2012-10-23 PT PT12781009T patent/PT2770989T/pt unknown
- 2012-10-23 HU HUE12781009A patent/HUE040145T2/hu unknown
- 2012-10-23 SI SI201231463T patent/SI2770989T1/sl unknown
- 2012-10-25 AR ARP120104004A patent/AR088535A1/es active IP Right Grant
- 2012-10-26 TW TW101139839A patent/TWI631099B/zh active
-
2013
- 2013-12-10 US US14/102,145 patent/US8993780B2/en active Active
-
2014
- 2014-04-23 IL IL232204A patent/IL232204B/en active IP Right Grant
- 2014-04-25 CL CL2014001080A patent/CL2014001080A1/es unknown
- 2014-05-05 ZA ZA2014/03222A patent/ZA201403222B/en unknown
- 2014-05-23 CO CO14111999A patent/CO6960509A2/es unknown
-
2015
- 2015-01-29 US US14/608,503 patent/US9351948B2/en active Active
-
2016
- 2016-04-26 US US15/138,823 patent/US9579307B2/en active Active
- 2016-07-29 JP JP2016150311A patent/JP6496689B2/ja active Active
-
2017
- 2017-01-18 US US15/408,643 patent/US9974772B2/en active Active
- 2017-10-23 AU AU2017251683A patent/AU2017251683C1/en active Active
- 2017-12-25 IL IL256555A patent/IL256555B/en active IP Right Grant
-
2018
- 2018-04-10 US US15/949,335 patent/US10172832B2/en active Active
- 2018-11-19 CY CY20181101220T patent/CY1121604T1/el unknown
- 2018-12-10 US US16/215,400 patent/US10993931B2/en active Active
-
2019
- 2019-03-11 JP JP2019043998A patent/JP6804580B2/ja active Active
- 2019-06-26 IL IL267659A patent/IL267659B/en unknown
- 2019-11-12 AU AU2019264555A patent/AU2019264555B2/en active Active
-
2020
- 2020-02-27 AR ARP200100544A patent/AR119698A2/es unknown
-
2021
- 2021-04-13 US US17/229,347 patent/US20220202777A1/en not_active Abandoned
-
2023
- 2023-09-29 US US18/478,718 patent/US20240285584A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019089849A5 (https=) | ||
| JP2019131569A5 (https=) | ||
| CA3045733C (en) | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases | |
| JP2020037585A5 (https=) | ||
| JP2015526458A5 (https=) | ||
| JP2009533356A5 (https=) | ||
| JP2012520249A5 (https=) | ||
| CR20220037A (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
| WO2020263967A8 (en) | 2h-indazole derivatives and their use in the treatment of disease | |
| JP2019505529A5 (https=) | ||
| JP2018537513A5 (https=) | ||
| JP2013544786A5 (https=) | ||
| CN110573161A (zh) | 用于治疗肌营养不良的方法的尼达尼布 | |
| RU2010116859A (ru) | ПРИМЕНЕНИЕ 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА В ЛЕЧЕНИИ РАССЕЯННОГО СКЛЕРОЗА И АУТОИММУННОГО МИЕЛИТА | |
| JPWO2020095971A5 (https=) | ||
| JP2012521966A5 (https=) | ||
| JP2019513814A5 (https=) | ||
| JP2023011735A5 (https=) | ||
| FI2765988T3 (fi) | Silmäkoostumus, joka sisältää bromfenaakkia, jolla on parannettu biologinen hyötyosuus | |
| AR092842A1 (es) | Tratamiento de enfermedades inflamatorias oculares usando laquinimod | |
| JP2021503451A5 (https=) | ||
| JP2019507786A5 (https=) | ||
| RU2016105310A (ru) | Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора | |
| PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| JP5017268B2 (ja) | 覚醒を改善する方法 |